Emerging Health Care Innovation Brief: Treating Stargardt Disease and Hypoxic-Ischemic Encephalopathy (August 31-September 13, 2023)
Download this Innovation Brief
Highlights
Highlights provide a timely synopsis of selected interesting developments emerging in the past 2 weeks from the information universe covered by the PCORI Health Care Horizon Scanning System (HCHSS). Information covers currently emerging innovations in patient-centered care that may or may not be directly related to the Topics to Watch. The views presented here are solely those of ECRI Horizon Scanning and have not been vetted by other stakeholders.
As flu season approaches and the United States experiences another wave of COVID-19, the US Food and Drug Administration (FDA) approved 2 vaccines targeting the Omicron variant XBB.1.5 on September 11, 2023. Data reported earlier in September suggest the updated vaccines should generate a robust immune response to the newest circulating variant, BA.2.86.
In women’s health news, results of a large cohort study published on August 29, 2023, found that treating postpartum depression with selective serotonin reuptake inhibitors benefits both mothers and their children up to 5 years after birth. On the same day, the first over-the-counter at-home menopause stage indicator was launched to help women determine their likely menopause stage.
On August 28, 2023, the FDA approved the first generic versions of lisdexamfetamine dimesylate (Vyvanse) to treat attention-deficit/hyperactivity disorder (ADHD) and binge-eating disorder. This may potentially ease the ongoing supply shortage of ADHD drugs. Furthering improved access to care, naloxone nasal spray (Narcan) is now available over-the-counter for opioid overdose reversal, and injectable buprenorphine (Sublocade) can be administered at certain retail pharmacies for patients with opioid use disorders.
Under the Inflation Reduction Act, the Centers for Medicare and Medicaid Services selected for Medicare price negotiations 10 drugs with high prescription costs to treat common conditions, potentially lowering drug costs starting in 2026.
Topics to Watch
ECRI Horizon Scanning has selected the topics below as those with potential for impact within the PCORI HCHSS’s focus areas in the United States within the next 3 years. All views presented are preliminary and based on readily available information at the time of writing. Because these topics are rapidly developing, we cannot guarantee the accuracy of this information after the date listed on this publication. In addition, all views expressed in the commentary section are solely those of ECRI Horizon Scanning and have not been vetted by other stakeholders. Topics are listed in alphabetical order.
MCO-010 to Treat Stargardt Disease
At a Glance
|
For a description and commentary about this topic/issue, download this Innovation Brief.
RLS-0071 to Treat Hypoxic-Ischemic Encephalopathy
At a Glance
|
For a description and commentary about this topic/issue, download this Innovation Brief.
Horizon scanning is a systematic process that serves as an early alert system to inform decision makers about possible future opportunities and threats. Health care horizon scanning identifies technologies, innovations, and trends with the potential to cause future shifts or disruptions—positive or negative—in areas such as access to care, care delivery processes, care setting, costs of care, current treatment models or paradigms, health disparities, health care infrastructure, public health, and patient health outcomes.
The PCORI Health Care Horizon Scanning System (HCHSS) conducts horizon scanning to better inform research investments at the Patient-Centered Outcomes Research Institute (PCORI). PCORI defines the HCHSS project scope to focus on interventions with high potential for disruption in the United States in the next 12 months within 6 focus areas: Alzheimer’s disease and other dementias, cancer, cardiovascular diseases, infectious diseases (including COVID-19), mental and behavioral health conditions, and rare diseases. In addition, the system captures high-level disruptive trends across all clinical areas, which may lead PCORI to expand the project scope to include other focus areas in the future.
The HCHSS produces 3 main outputs:
- Emerging Health Care Innovation Brief provides ECRI Horizon Scanning with a vehicle to inform PCORI and the public in a timely manner of important topics of interest identified during ongoing scanning and topic identification or through the ECRI stakeholder survey process.
- PCORI’s Horizon Scanning Database offers health care decision makers findings about advancements in the HCHSS’s 6 focus areas. This database can be used by patients, care partners, and others to track advancements in care options.
- High Potential Disruption Reports (every 6 months) for individuals with vested interests in new technologies, services, and innovations. It might provide critical insights and information about the areas in which they have a vested interest, which might include their vision and plans for how they intend to adopt an innovation. These reports highlight those topics that stakeholders (eg, patients, physicians, nurses, allied health professionals, public health professionals, first responders, health systems experts, clinical engineers, researchers, business and finance professionals, and information technology professionals) identified as having potential for high disruption.
In January 2023, the HCHSS Biweekly COVID-19 Scans were broadened in scope to include any emerging intervention in the HCHSS and renamed as the Emerging Health Care Innovation Brief.
Back to Main Page Download this Innovation Brief
We welcome your comments on this Innovation Brief at [email protected].
Posted: September 22, 2023
What's Happening at PCORI?
The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.
Image
